Your session is about to expire
← Back to Search
Neural Stimulator
DBS Parameter Optimization for Epilepsy
Phase < 1
Recruiting
Led By Robert McGovern, MD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year from baseline
Awards & highlights
Study Summary
This trial will develop a platform for more effective deep brain stimulation (DBS) for epilepsy by optimizing the INS settings for each patient based on power spectral density measures.
Who is the study for?
This trial is for patients with epilepsy that doesn't respond to medication and who already have a deep brain stimulator implanted. It's not suitable for individuals with severe dementia as determined by the study investigator.Check my eligibility
What is being tested?
The study tests how changing settings on an implantable neural stimulator can better control seizures in epilepsy patients. Different orders of stimulation (PS and OS) are being compared to find the most effective parameter adjustments.See study design
What are the potential side effects?
While specific side effects aren't listed, deep brain stimulation may cause headache, dizziness, change in mood or behavior, speech problems, or unintended movements.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year from baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year from baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Difference in broadband power with different settings
Difference in frequency band-specific low-frequency power (LFP) with different settings
Secondary outcome measures
Identify all seizures
Scores on Montreal Cognitive Assessment, MoCA
Scores on epilepsy-specific quality of life questionnaire (QOLIE-10P)
Trial Design
3Treatment groups
Experimental Treatment
Group I: Stimulation Group CExperimental Treatment1 Intervention
Participants with already implanted DBS will receive stimulation order 1. OS, OS, PS.
Group II: Stimulation Group BExperimental Treatment1 Intervention
Participants with already implanted DBS will receive stimulation order 1. OS, PS, OS.
Group III: Stimulation Group AExperimental Treatment1 Intervention
Participants with already implanted DBS will receive stimulation order 1. PS, OS, OS.
Find a Location
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,379 Previous Clinical Trials
1,588,476 Total Patients Enrolled
Robert McGovern, MDPrincipal InvestigatorUniversity of Minnesota
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My epilepsy does not improve with medication.
Research Study Groups:
This trial has the following groups:- Group 1: Stimulation Group C
- Group 2: Stimulation Group A
- Group 3: Stimulation Group B
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available slots remaining for the clinical trial?
"According to current information on clinicaltrials.gov, this medical trial is no longer accepting participants. This study was initially posted in August 1st 2023 and last updated on August 5th 2022, however there are presently 265 other trials actively recruiting patients."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger